Meetings and Studies: Review of the 24th World Congress of the International Society of Hair Restoration Surgery

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

Finasteride can cause dry eyes and vision issues due to its impact on the meibomian glands. Users have mixed experiences, with some experiencing eye discomfort and others having no side effects.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.